CNCR vs. WDNA
CNCR (Loncar Cancer Immunotherapy ETF) and WDNA (WisdomTree BioRevolution Fund) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while WDNA tracks the WisdomTree BioRevolution Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.45%/yr for WDNA.
Performance
CNCR vs. WDNA - Performance Comparison
Loading charts...
Returns By Period
CNCR
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
WDNA
- 1D
- -2.61%
- 1M
- -1.27%
- YTD
- 4.55%
- 6M
- 9.65%
- 1Y
- 45.95%
- 3Y*
- 2.03%
- 5Y*
- —
- 10Y*
- —
CNCR vs. WDNA - Yearly Performance Comparison
| 2026 (YTD) | |
|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% |
WDNA WisdomTree BioRevolution Fund | -1.26% |
CNCR vs. WDNA - Sectors Allocation Comparison
Sectors
CNCR
WDNA
Healthcare
Financial Services
-
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
Energy
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
CNCR
WDNA
Financial Services
CNCR
WDNA
-
Basic Materials
CNCR
-
WDNA
Communication Services
CNCR
-
WDNA
-
Consumer Cyclical
CNCR
-
WDNA
-
Consumer Defensive
CNCR
-
WDNA
Energy
CNCR
-
WDNA
Industrials
CNCR
-
WDNA
-
Real Estate
CNCR
-
WDNA
-
Technology
CNCR
-
WDNA
-
Utilities
CNCR
-
WDNA
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CNCR vs. WDNA — Risk / Return Rank
CNCR
WDNA
CNCR vs. WDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Sharpe Ratios by Period
| CNCR | WDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 1.81 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | — | -0.22 | — |
Drawdowns
CNCR vs. WDNA - Drawdown Comparison
The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum WDNA drawdown of -58.87%. Use the drawdown chart below to compare losses from any high point for CNCR and WDNA.
Loading charts...
Drawdown Indicators
| CNCR | WDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | 0.00% | -58.87% | +58.87% |
Max Drawdown (1Y)Largest decline over 1 year | — | -11.70% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -38.25% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -58.87% | — |
Current DrawdownCurrent decline from peak | 0.00% | -32.70% | +32.70% |
Average DrawdownAverage peak-to-trough decline | 0.00% | -35.65% | +35.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 5.13% | — |
Volatility
CNCR vs. WDNA - Volatility Comparison
Loading charts...
Volatility by Period
| CNCR | WDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 6.67% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 16.50% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 0.00% | 25.60% | -25.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 0.00% | 25.05% | -25.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 0.00% | 25.05% | -25.05% |
CNCR vs. WDNA - Expense Ratio Comparison
CNCR has a 0.79% expense ratio, which is higher than WDNA's 0.45% expense ratio.
Dividends
CNCR vs. WDNA - Dividend Comparison
CNCR has not paid dividends to shareholders, while WDNA's dividend yield for the trailing twelve months is around 4.37%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
WDNA WisdomTree BioRevolution Fund | 4.37% | 4.57% | 0.75% | 0.80% | 0.38% | 0.10% |
Frequently Asked Questions
On fees, WDNA is cheaper at 0.45% per year. The better choice depends on whether you care most about return, fees, risk, or income.
WDNA is cheaper with a 0.45% expense ratio, compared with 0.79% for CNCR.
WDNA has the higher dividend yield at 4.37%, compared with 0.00% for CNCR.
CNCR tracks Loncar Cancer Immunotherapy Index, while WDNA tracks WisdomTree BioRevolution Index. They also come from different issuers: Exchange Traded Concepts and WisdomTree. Their fees differ too: 0.79% for CNCR and 0.45% for WDNA.
Find the right allocation for CNCR and WDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer